Spatial characterization and quantification of CD40 expression across cancer types.
CD40
Cancer cells
NSCLC
Ovarian
Pancreatic
Quantitative immunofluorescence
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Mar 2023
09 Mar 2023
Historique:
received:
21
10
2022
accepted:
14
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
CD40, a TNF receptor family member, is expressed by a variety of immune cells and is involved in the activation of both adaptive and innate immune responses. Here, we used quantitative immunofluorescence (QIF) to evaluate CD40 expression on the tumor epithelium of solid tumors in large patient cohorts of lung, ovarian, and pancreatic cancers. Tissue samples from nine different solid tumors (bladder, breast, colon, gastric, head and neck, non-small cell lung cancer (NSCLC), ovarian, pancreatic and renal cell carcinoma), constructed in tissue microarray format, were initially assessed for CD40 expression by QIF. CD40 expression was then evaluated on the large available patient cohorts for three of the tumor types demonstrating high CD40 positivity rate; NSCLC, ovarian and pancreatic cancer. The prognostic impact of CD40 expression on tumor cells was also investigated. CD40 expression on tumor cells was found to be common, with 80% of the NSCLC population, 40% of the ovarian cancer population, and 68% of the pancreatic adenocarcinoma population displaying some degree of CD40 expression on cancer cells. All of three of these cancer types displayed considerable intra-tumoral heterogeneity of CD40 expression, as well as partial correlation between expression of CD40 on tumor cells and on surrounding stromal cells. CD40 was not found to be prognostic for overall survival in NSCLC, ovarian cancer, or pancreatic adenocarcinoma. The high percentage of tumor cells expressing CD40 in each of these solid tumors should be considered in the development of therapeutic agents designed to target CD40.
Sections du résumé
BACKGROUND
BACKGROUND
CD40, a TNF receptor family member, is expressed by a variety of immune cells and is involved in the activation of both adaptive and innate immune responses. Here, we used quantitative immunofluorescence (QIF) to evaluate CD40 expression on the tumor epithelium of solid tumors in large patient cohorts of lung, ovarian, and pancreatic cancers.
METHODS
METHODS
Tissue samples from nine different solid tumors (bladder, breast, colon, gastric, head and neck, non-small cell lung cancer (NSCLC), ovarian, pancreatic and renal cell carcinoma), constructed in tissue microarray format, were initially assessed for CD40 expression by QIF. CD40 expression was then evaluated on the large available patient cohorts for three of the tumor types demonstrating high CD40 positivity rate; NSCLC, ovarian and pancreatic cancer. The prognostic impact of CD40 expression on tumor cells was also investigated.
RESULTS
RESULTS
CD40 expression on tumor cells was found to be common, with 80% of the NSCLC population, 40% of the ovarian cancer population, and 68% of the pancreatic adenocarcinoma population displaying some degree of CD40 expression on cancer cells. All of three of these cancer types displayed considerable intra-tumoral heterogeneity of CD40 expression, as well as partial correlation between expression of CD40 on tumor cells and on surrounding stromal cells. CD40 was not found to be prognostic for overall survival in NSCLC, ovarian cancer, or pancreatic adenocarcinoma.
CONCLUSIONS
CONCLUSIONS
The high percentage of tumor cells expressing CD40 in each of these solid tumors should be considered in the development of therapeutic agents designed to target CD40.
Identifiants
pubmed: 36894898
doi: 10.1186/s12885-023-10650-7
pii: 10.1186/s12885-023-10650-7
pmc: PMC9996913
doi:
Substances chimiques
CD40 Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Amgen
ID : GR109016
Informations de copyright
© 2023. The Author(s).
Références
Cancer Res. 2016 Nov 1;76(21):6266-6277
pubmed: 27634762
ESMO Open. 2019 Jun 12;4(Suppl 3):e000510
pubmed: 31275618
Hum Immunol. 2014 Jul;75(7):614-20
pubmed: 24801648
Biotechniques. 2020 Dec;69(6):460-468
pubmed: 32852223
Cell Immunol. 2003 Feb;221(2):81-8
pubmed: 12747948
Neoplasma. 2011;58(3):189-97
pubmed: 21391734
Mol Pathol. 2002 Apr;55(2):110-20
pubmed: 11950960
J Immunol. 1999 Apr 1;162(7):4140-7
pubmed: 10201939
Oncol Lett. 2020 Nov;20(5):176
pubmed: 32934743
Clin Cancer Res. 1998 Aug;4(8):1843-9
pubmed: 9717810
Hum Vaccin Immunother. 2020;16(2):377-387
pubmed: 31403344
Mol Cancer. 2021 Jun 6;20(1):85
pubmed: 34092233
J Pathol. 1999 May;188(1):38-43
pubmed: 10398138
Cancer Immunol Immunother. 2000 May;49(2):101-8
pubmed: 10823420
Cancer. 2008 Aug 1;113(3):530-41
pubmed: 18548529
Clin Cancer Res. 1999 Aug;5(8):2261-70
pubmed: 10473114
Clin Cancer Res. 2001 Mar;7(3):691-703
pubmed: 11297266
Nat Cancer. 2022 Mar;3(3):287-302
pubmed: 35190724
Oncol Rep. 2012 Jul;28(1):262-8
pubmed: 22552529
Cancer Immunol Res. 2019 Nov;7(11):1864-1875
pubmed: 31462409
J BUON. 2017 Jul-Aug;22(4):894-899
pubmed: 29155517
Int J Mol Sci. 2009 Sep 04;10(9):3900-3917
pubmed: 19865524
Mol Cell Biol. 2000 Aug;20(15):5503-15
pubmed: 10891490
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Immunol Rev. 2009 May;229(1):152-72
pubmed: 19426221
Blood. 1999 May 1;93(9):2999-3007
pubmed: 10216096